U.S. FDA advisers back Pfizer COVID-19 vaccine authorization |
Clinical News
eMediNexus Coverage from: 
U.S. FDA advisers back Pfizer COVID-19 vaccine authorization

1 Read Comments                

A panel of outside advisers to the U.S. Food and Drug Administration has voted to endorse emergency use of Pfizer’s COVID-19 vaccine, thus paving the way for the agency to authorize the vaccine.

The committee voted 17-4 that the known benefits of the vaccine outweigh the risks of taking the shot for individuals aged 16 and above, with 1 member of the panel abstaining. It is expected that FDA will authorize emergency use within days. Distribution and vaccinations in the United States are expected to begin almost immediately following the authorization. While it was not clear why four panelists voted against authorization, several mentioned that they were not comfortable with the inclusion of 16 and 17 year olds… (Reuters, December 11, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now